Updated: April 13, 2021 09:35 PM
Created: April 13, 2021 09:13 PM
(CNBC/WHEC) — Moderna Tuesday announced its COVID-19 vaccine is more than 90% effective at protecting against the virus and more than 95% effective against severe illness from the virus up to six months after the second dose.
The company cited updated data from its phase three clinical trial, which includes more than 900 COVID-19 cases and more than 100 severe cases through April 9.
The Food and Drug Administration usually requires six months of data for full FDA approval of a drug.
The Moderna COVID-19 vaccine, as well as the Pfizer and Johnson & Johnson vaccines are currently being used under an Emergency Use Authorization, which can be revoked at any time. Only two months of follow-up safety data is required to get Emergency Use Authorization.
Pfizer's COVID-19 vaccine also has six months of data.
The company also said Tuesday its trial testing the vaccine in adolescents ages 12 to 17 is now fully enrolled, with about 3,000 participants in the U.S. and it's still enrolling participants in a trial testing the vaccine in children who are six months old to 11 years old.
The University of Rochester Medical Center is participating in the trial for children ages six months to 11 years old. Click here for more information about the trial.
Copyright 2021 - WHEC-TV, LLC A Hubbard Broadcasting Company